Showing results (61-70 of 103) with videos related to
Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2008
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapyStephen Johnston, Maureen Trudeau, Bella Kaufman, et al.Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.Breast Cancer Research and Treatment|April 23, 2010
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyLori J Pierce, Kelly-Anne Phillips, Kent A Griffith, et al.Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.Proceedings of the National Academy of Sciences of the United States of America|September 7, 2014
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman, et al.Breast (Edinburgh, Scotland)|March 28, 2016
Second international consensus guidelines for breast cancer in young women (BCY2)Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerStan B Kaye, Jan Lubinski, Ursula Matulonis, et al.Cancer Immunology, Immunotherapy : CII|March 22, 2020
TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patientsMaya Dadiani, Daniela Necula, Smadar Kahana-Edwin, et al.Molecular Carcinogenesis|September 16, 2022
Divergence of mutational signatures in association with breast cancer subtypeGili Perry, Maya Dadiani, Smadar Kahana-Edwin, et al.The New England Journal of Medicine|December 29, 2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer, John Forster, Deborah Lindquist, et al.Pageof 11